Brief: Spectrum Pharmaceuticals Announces Late-Breaking Oral Presentation Of Data For Poziotinib
13/09/2021 12:30
Sept 13 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O :
* SPECTRUM PHARMACEUTICALS ANNOUNCES LATE-BREAKING ORAL
PRESENTATION OF DATA FOR POZIOTINIB IN FIRST-LINE NSCLC PATIENTS
WITH HER2 EXON 20 MUTATIONS AT THE UPCOMING ESMO CONGRESS 2021
Source text for Eikon: ID:nBw2Nv7yxa
Further company coverage: SPPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary